Pluristem Therapeutics announced that preclinical results for its Placental eXpanded, or PLX, RAD cells in the treatment of bone marrow disease have been published in peer reviewed journal PLOS ONE. The findings of the published study suggest that intramuscular treatment with Pluristem's PLX-RAD cells may serve as a highly effective "off the shelf" therapy to mitigate ARS. The treatment of intramuscular injection of PLX-RAD cells increased the survival of 7.7Gy irradiated mice from about 27% to about 98%.
- Finance Trading
- Pluristem Therapeutics